Barry Bunin of Collaborative Drug Discovery, Madeline Ball of Personal Genome Project, Mark Hanhel of Digital Science, and Pek Lum of Ayasdi discuss big data, the future of biomedicine and innovation in biopharma research.
Madeleine Price Ball, PhD, is Director of Biology with the Personal Genome Project. She also posts on the PGP blog. Her graduate work was in the Church Lab, developing high throughput DNA methylation profiling technology. She is involved in developing the computational and literature review methods used to interpret PGP genomes and is a leading developer of GET-Evidence, the PGP’s system for genome interpretation. She also works on PGP issues related to participation, including communication, informed consent, and data and sample collection
Madeleine likes to edit Wikipedia under her real name.
In case you’re curious about distant past – Madeleine attended Caltech in ’97-’98 & ’99-’02, graduating with a Biology major. They still made her do some physics though. She was a Mole. Before this she attended La Jolla High School, as did her three awesome younger siblings.
Dr. Barry Bunin, CEO & President of Collaborative Drug Discovery Inc.
(www.collaborativedrug.com) helps scientists in secure collaborative groups more rapidly
develop drug candidates for commercial and humanitarian markets. Thousands of researchers
worldwide use CDD today. Dr. Bunin and CDD received funding in 2008 to support a
global community of leading TB researchers from the Gates Foundation (BMGF). He co-
authored “Chemoinformatics: Theory, Practice, and Products”, a text that overviews modern
chemoinformatics technologies and “The Combinatorial Index”, a widely used text on high-
throughput chemical synthesis. Dr. Bunin was an Entrepreneur-in-Residence at Eli Lilly and the
founding CEO, President, & CSO of Libraria. In the lab, Dr. Bunin did medicinal chemistry
developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals and RGD
mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin is on a patent for Carfilzomib – a selective
proteasome inhibitor now in phase 3 clinical trials for multiple myeloma. Dr. Bunin received his
Ph.D. at Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with
Professor Jonathan Ellman.
Mark joins Digital Science straight out of academia, having just completed his PhD in stem cell biology at Imperial College London, having previously studied genetics in both Newcastle and Leeds. He is genuinely passionate about open science and the potential it has to revolutionise the research community. Outside of science and computers, he tries to spend the majority of his time watching football and occasionally attempting to play it.
Pek Lum joined Ayasdi in September 2010 to start and lead the Life Sciences sector where she is developing the vision and business strategy. Prior to joining Ayasdi, she spent 10 years at Rosetta Inpharmatics/ Merck & Co. where her research in systems biology has contributed to the discoveries of new targets, biomarkers and the understanding of complex diseases. Her work has been widely published in leading scientific journals. She received her Ph.D. from the University of Washington.